Abstract:G protein-coupled receptors (GPCRs) constitute a superfamily of membrane proteins which have in common the presence of 7 transmembrane α-helices linked by several intra- and extracellular loops. This particular structure is important for extracellular stimulus recognition through the amino acids forming the extracellular loops (class B, C and F of GPCRs) or by the transmembrane α-helices (class A and B of GPCRs). Their structure is also essential for signal transduction via intracellular proteins (G proteins, arrestins and kinases – GRKs-) [ Citation 1 ]. These proteins are attached to the intracellular loops and/or to the intracellular regions of the α-helices of the GPCRs, even when they are not activated by extracellular ligands or drugs. When GPCRs are activated, there is a modification of their protein structure that allosterically transmits the signal from the binding pocket to those intracellular effector proteins [ Citation 2 , Citation 3 ]. Importantly, GPCRs participate in more than 80% of the signal transduction processes that occur across plasma membrane. As more than 800 GPCRs have been identified in the human genome, this superfamily of receptors constitutes the largest protein superfamily codified in our genome. Most of these receptors are activated by sensory stimuli, mainly smell, and around 360 are stimulated by extrasensorial ligands, from small molecules to large proteins. Furthermore, more than 90% of GPCRs are expressed in the CNS and, thereby, are involved in the vast majority of neuronal functions [ Citation 4 ]. Their protein structure alteration by polymorphisms, mutations and posttranslational modifications, among others, can affect their ability to be activated by extracellular signals and/or their capacity to transduce these signals intracellularly. Therefore, structural alterations have been associated with many pathologies, including degenerative, neurological, inflammatory and cancerous [ Citation 5 ]. Moreover, alterations in protein structure can be associated with a decrease in drug therapeutic efficacy and with the appearance of patient-related side effects [ Citation 6 ]. Given the aforementioned, currently, GPCRs constitute the most important superfamily of membrane proteins pharmacologicaly targeted in clinical practice. Interestingly, among all the drugs approved by the Food and Drug Administration (FDA), around 35% target GPCRs [ Citation 7 , Citation 8 ]. Until 2017, the FDA and the European Medicines Agency (EMA) had approved 475–704 drugs for 108–134 different GPCRs, mainly aminergic and opioid receptors (e.g. cariprazine, brexpiprazole, naloxegol, or naldemedine) [ Citation 7 , Citation 8 ]. Moreover, there are 321 drugs targeting GPCRs in clinical trials (e.g. LJPC-501, INT-767, or RX-10045), 66 of which acting on GPCRs that are not currently a target of any approved drug [ Citation 7 ]. Between 2011 and 2015 the sales of drugs acting on GPCRs amounted to 917 billion USD [ Citation 9 ]. The development of such a great number of dugs has been achieved applying classical and modern techniques and methodologies along with in-silico and experimental approaches or a combination of both. These drugs activate, block or modulate (increasing or decreasing) the function of GPCRs targeting their orthosteric or allosteric centers (see section 4). In 2017, Gloriam and collaborators [ Citation 7 ] published a study about drugs acting on GPCRs approved or in clinical trials. These authors pointed out that there is a tendency to search for drugs more selective than classical drugs that usually have a polypharmacology with an average of 4–10 possible targets. They also state that aproximately 56% of non-sensory GPCRs are clinically unexplored. Among them, a substantial proportion (27%) are orphan GPCRs, which are receptors lacking known endogenous ligands. Therefore, the study of function and pharmacology of orphan GPCRs could potentially unravel new targets for the treatment of numerous pathologies. In fact, several drugs targeting orphan GPCRs are in clinical trials (e.g. G -Abstract Truncated-

Therapeutic Targeting of Endosomal G-Protein-Coupled Receptors

Distinct Conformations of GPCR–β-arrestin Complexes Mediate Desensitization, Signaling, and Endocytosis

G Protein–Coupled Receptor (GPCR) Expression in Native Cells: “Novel” endoGPCRs as Physiologic Regulators and Therapeutic Targets

Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission

GPCR signalling from within the cell

Visualization of endogenous G proteins on endosomes and other organelles

Pharmacologically Targeting Intracellular Allosteric Sites of GPCRs for Drug Discovery.

Endosomal Phosphatidylinositol 3-Kinase Is Essential for Canonical GPCR Signaling

What are the current trends in G protein-coupled receptor targeted drug discovery?

Regulation of Receptor Trafficking by GRKs and Arrestins

Targeting G protein–coupled receptor kinases to G protein–coupled receptors

Therapeutic Potential of Targeting ß-Arrestin

Are GPCRs Still a Source of New Targets?

GPCRs in Autocrine and Paracrine Regulations

Compartmentalized GPCR Signaling from Intracellular Membranes

Minireview: Targeting GPCR Activated ERK Pathways for Drug Discovery

Discovery and design of G protein-coupled receptor targeting antibodies

G Protein-Coupled Receptor Signaling: Transducers and Effectors

Orphan G Protein-Coupled Receptors (gpcrs): Biological Functions and Potential Drug Targets

β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders